2-(2-(3-(3-(tert-Butyl)ureido)-5-chloro-6-(2-cyclohexylethyl)-2-oxopyrazin-1(2H)-yl)acetamido)benzoicacid

ID: ALA3797877

Chembl Id: CHEMBL3797877

PubChem CID: 127045739

Max Phase: Preclinical

Molecular Formula: C26H34ClN5O5

Molecular Weight: 532.04

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CC(C)(C)NC(=O)Nc1nc(Cl)c(CCC2CCCCC2)n(CC(=O)Nc2ccccc2C(=O)O)c1=O

Standard InChI:  InChI=1S/C26H34ClN5O5/c1-26(2,3)31-25(37)30-22-23(34)32(15-20(33)28-18-12-8-7-11-17(18)24(35)36)19(21(27)29-22)14-13-16-9-5-4-6-10-16/h7-8,11-12,16H,4-6,9-10,13-15H2,1-3H3,(H,28,33)(H,35,36)(H2,29,30,31,37)

Standard InChI Key:  PNHKGAONIQWINY-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA3797877

    ---

Associated Targets(non-human)

Hepatitis C virus (23859 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NS3 NS3 protease (146 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NS3 NS3 (1121 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 532.04Molecular Weight (Monoisotopic): 531.2248AlogP: 4.67#Rotatable Bonds: 8
Polar Surface Area: 142.42Molecular Species: ACIDHBA: 6HBD: 4
#RO5 Violations: 1HBA (Lipinski): 10HBD (Lipinski): 4#RO5 Violations (Lipinski): 1
CX Acidic pKa: 3.56CX Basic pKa: CX LogP: 4.59CX LogD: 1.23
Aromatic Rings: 2Heavy Atoms: 37QED Weighted: 0.39Np Likeness Score: -1.13

References

1. Belfrage AK, Abdurakhmanov E, Kerblom E, Brandt P, Oshalim A, Gising J, Skogh A, Neyts J, Danielson UH, Sandström A..  (2016)  Discovery of pyrazinone based compounds that potently inhibit the drug-resistant enzyme variant R155K of the hepatitis C virus NS3 protease.,  24  (12): [PMID:27160057] [10.1016/j.bmc.2016.03.066]
2. Belfrage AK, Abdurakhmanov E, Åkerblom E, Brandt P, Alogheli H, Neyts J, Danielson UH, Sandström A..  (2018)  Pan-NS3 protease inhibitors of hepatitis C virus based on an R3-elongated pyrazinone scaffold.,  148  [PMID:29477077] [10.1016/j.ejmech.2018.02.032]

Source